Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Levosimendan (Primary)
- Indications Amyotrophic lateral sclerosis; Motor neuron disease
- Focus Therapeutic Use
- Acronyms LEVALS
- Sponsors Orion
- 19 Sep 2017 Trial has been completed in Netherlands.
- 04 Aug 2017 This trial has been completed in Ireland (end date: 11 May 2017).
- 19 Jul 2017 Trial has been completed in Germany.